Cargando…
Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros
BACKGROUND: The development of therapies for sickle cell disease has received special attention, particularly those that reduce the polymerization of hemoglobin S. Hydroxyurea is a commonly used medication because it has the ability to raise levels of fetal hemoglobin, decrease the frequency of vaso...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Associação Brasileira de Hematologia e Hemoterapia
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520633/ https://www.ncbi.nlm.nih.gov/pubmed/23284256 http://dx.doi.org/10.5581/1516-8484.20110029 |